Tag: Kuma062
Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics
Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth ... Read More
PvP Biologics initiates Kuma062 human trials for celiac disease treatment
PvP Biologics, a US pharma company, has initiated two phase 1 clinical trials for Kuma062 to evaluate the recombinant enzyme for celiac disease treatment. According ... Read More